Residency · Residency · Chronic Pain Management

Methadone for Chronic Pain

Introduction

Methadone is a synthetic opioid with a pharmacologic profile unlike any other opioid in clinical use. Beyond its full mu-opioid receptor agonism, methadone possesses NMDA receptor antagonist activity, serotonin-norepinephrine reuptake inhibition, and excellent oral bioavailability. These multimodal properties make it a potent analgesic for complex chronic pain states, particularly those involving neuropathic components or opioid-induced hyperalgesia. The flip side of this utility is that methadone's unpredictable and highly variable pharmacokinetics, potential for QTc prolongation, and non-linear dose-response relationship demand a level of clinical expertise well beyond routine opioid prescribing.

Unique Pharmacology

Mu-Opioid Receptor Agonism

Methadone is a full agonist at the mu-opioid receptor with high binding affinity. It exists as a racemic mixture of two isomers: R-methadone (levomethadone), which is primarily responsible for opioid analgesia and is approximately 8-50 times more potent than S-methadone at the mu receptor, and S-methadone, which contributes primarily to NMDA antagonism and serotonin-norepinephrine reuptake inhibition.

NMDA Receptor Antagonism

Both isomers block the NMDA receptor in a non-competitive fashion, though S-methadone is the more potent contributor. This property provides anti-hyperalgesic and anti-allodynic effects that are independent of opioid receptor activation. By attenuating central sensitization, wind-up phenomena, and opioid-induced hyperalgesia, NMDA antagonism makes methadone particularly effective in neuropathic pain states where central sensitization is a key driver of symptoms.

Serotonin-Norepinephrine Reuptake Inhibition

Methadone inhibits the reuptake of serotonin and norepinephrine in descending pain modulatory pathways, mirroring the analgesic mechanism of duloxetine and other SNRI antidepressants. This provides additional benefit in neuropathic and centralized pain syndromes and contributes to methadone's efficacy in pain states that respond poorly to other opioids.

<image>Detailed molecular pharmacology diagram showing methadone's three mechanisms of action at the neuronal synapse: (1) mu-opioid receptor binding on the postsynaptic neuron with G-protein activation, (2) NMDA receptor channel blockade preventing calcium influx, and (3) presynaptic serotonin and norepinephrine transporter inhibition, with R-methadone and S-methadone contributions labeled at each site</image>

Variable Pharmacokinetics

Absorption and Distribution

Methadone has an oral bioavailability of 80-95%, substantially higher than morphine's roughly 30%. It is highly lipophilic with extensive tissue distribution and a large volume of distribution (1-8 L/kg). The drug accumulates in fat, liver, kidney, brain, and muscle, creating tissue reservoirs that contribute to its prolonged and sometimes unpredictable effects.

Half-Life Variability

The elimination half-life of methadone ranges from 8 to 59 hours, with a mean of approximately 22-25 hours. This extraordinary interindividual variability is driven by differences in CYP enzyme activity, body composition, age, hepatic function, and genetic polymorphisms. Steady state is not reached until 5-7 days after dose initiation or adjustment. A critical clinical distinction is that the analgesic duration (4-8 hours) is significantly shorter than the elimination half-life, which means a patient may need to take the drug every 8 hours for pain relief but may accumulate it over days, creating a risk of delayed toxicity.

Metabolism

Methadone is primarily metabolized by CYP3A4, with contributions from CYP2B6, CYP2D6, and CYP2C19. This creates a long list of clinically significant drug interactions. CYP3A4 inducers such as rifampin, carbamazepine, and phenytoin can reduce methadone levels and precipitate withdrawal. CYP3A4 inhibitors such as fluconazole, erythromycin, and grapefruit juice can increase methadone levels and raise toxicity risk. CYP2B6 polymorphisms significantly affect S-methadone metabolism and may influence QTc prolongation risk.

QTc Prolongation Risk

Mechanism

Methadone, particularly the S-isomer, blocks the human ether-a-go-go-related gene (hERG) potassium channel. hERG channel blockade prolongs cardiac repolarization, manifesting as QTc prolongation on ECG. In susceptible patients, this can lead to torsades de pointes, a polymorphic ventricular tachycardia that can be fatal.

Risk Factors for QTc Prolongation

The risk is dose-dependent and generally higher at doses above 100 mg/day, though QTc prolongation can occur at any dose. Additional risk factors include concomitant medications that prolong the QTc interval (antipsychotics, fluoroquinolones, ondansetron, tricyclic antidepressants), electrolyte abnormalities (hypokalemia, hypomagnesemia, hypocalcemia), structural heart disease, heart failure, bradycardia, female sex, hepatic impairment, and CYP2B6 poor metabolizer status.

Monitoring Protocol

A baseline ECG should be obtained before initiating methadone. Repeat ECGs are recommended at 30 days, after significant dose increases, and annually. If the QTc exceeds 450 ms, the risk-benefit should be discussed, contributing factors eliminated, and dose reduction considered. If the QTc exceeds 500 ms or increases by more than 60 ms from baseline, discontinuation or significant dose reduction should be strongly considered. Electrolytes (potassium, magnesium) should be checked at baseline and periodically.

<image>Clinical monitoring flowchart for methadone-associated QTc prolongation, showing the stepwise approach from baseline ECG through dose-dependent monitoring intervals, with decision branch points at QTc thresholds of 450 ms and 500 ms, actions including electrolyte correction, drug interaction review, dose adjustment, and methadone discontinuation with alternative opioid selection</image>

Dosing Challenges

Non-Linear Equianalgesic Ratios

The equianalgesic ratio of morphine to methadone is not fixed -- it changes dramatically with the dose of the prior opioid. At low morphine equivalent doses (less than 60 mg/day), the ratio is approximately 4:1. At moderate doses (60-200 mg/day), it shifts to approximately 8:1. At high doses (200-500 mg/day), it may be 12:1 or higher, and at very high doses (above 500 mg/day), the ratio can exceed 20:1.

Initiation and Titration

For opioid-naive patients, methadone is started at a conservative dose of 2.5-5 mg every 8-12 hours. The dose should not be increased more frequently than every 5-7 days to allow time for steady-state accumulation. The most dangerous period is days 2-7 after initiation or dose increase, when tissue accumulation can produce delayed respiratory depression even though the patient seemed fine on day one. Patients and caregivers must be educated about signs of over-sedation and when to seek emergency care.

Rotation to Methadone

Two main methods are used for opioid rotation to methadone. The stop-and-go method discontinues the prior opioid and starts methadone at a calculated reduced dose. The three-day crossover method reduces the prior opioid by one-third each day while adding methadone in equivalent one-third increments. Regardless of method, the calculated methadone dose should be reduced by 25-75% for safety, and breakthrough analgesia with a short-acting non-methadone opioid should be provided during the transition.

Monitoring Requirements

Patients on methadone require ECG monitoring at baseline, at 30 days, after dose changes, and annually. Liver function tests should be checked at baseline and periodically since methadone is hepatically metabolized. Drug interactions must be reviewed at every visit given the extensive CYP-mediated metabolism. Urine drug testing, PDMP review, and clinical assessment of pain scores, functional status, sedation level, and signs of toxicity or misuse should follow the same protocol as any chronic opioid therapy.

Clinical Pearls

Methadone's long and variable half-life is both its greatest clinical asset (sustained analgesia) and its most dangerous feature (delayed respiratory depression from accumulation); the first week of therapy or dose escalation is the highest-risk period. Standard equianalgesic conversion tables should never be used for methadone -- the morphine-to-methadone ratio is highly dose-dependent, and miscalculation can be fatal. Methadone is an excellent choice for neuropathic pain and opioid-induced hyperalgesia because of its NMDA antagonist and SNRI properties, but these benefits demand prescriber expertise and a clear monitoring protocol. A baseline ECG and a defined QTc monitoring plan are non-negotiable before starting methadone. Finally, methadone prescribed for pain uses a standard DEA license; the separate SAMHSA/OBOT regulations apply only to methadone dispensed for opioid use disorder through licensed opioid treatment programs.

References

1. Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence. Journal of Pain. 2014;15(4):321-337.
2. Fredheim OM, Moksnes K, Borchgrevink PC, Kaasa S, Dale O. Clinical pharmacology of methadone for pain. Acta Anaesthesiologica Scandinavica. 2008;52(7):879-889.
3. Weschules DJ, Bain KT. A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Medicine. 2008;9(5):595-612.
4. Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC. QTc interval screening in methadone treatment. Annals of Internal Medicine. 2009;150(6):387-395.

Read this lecture as Markdown